Molecular and Cellular Mechanisms of the In-stent-thrombosis. Is it Possible to Predict a In-stent-thrombosis Using Biomarkers?
Trial Snapshot
- Phase
- Not Applicable
- Status
- Withdrawn
- Sponsor
- RWTH Aachen University
- Locations
- 1
- Primary Endpoint
- The aim of this study is to establish diagnostic markers for prediction of SAT and LT, respectively, by identification of CD39 and CD73-activity and EPC-number and function, respectively.
Study Overview
Brief Summary
In-Stent-Thrombosis is a rare but serious complication after implantation of stents during PTCA.
Detailed Description
In this prospective, open, not-randomized, controlled single-center pilot study 80 patients having had an in-stent-thrombosis (40 sub-acute thromboses (SAT), 40 late thromboses (LT)) and a control group of 80 patients having not developed a thrombosis will be compared.
The aim of this study is the establishment of diagnostic markers vor prediction of SAT (detection of CD39- and CD73-activity, respectively)and of LT (EPC-number and function, respectively) correspondingly aiming at the early identification of patients with high risk for developing an in-stent-thrombosis.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •patients having developed an SAT or LT after stent implantation using PTCA
Exclusion Criteria
- •instabel coronary heart diseases,
- •systemic autoimmune diseases,
- •rheumatic diseases,
- •impaired kidney or liver function,
- •surgery within the last 3 months,
- •pregnant or lactating women
Outcomes
Primary Outcomes
The aim of this study is to establish diagnostic markers for prediction of SAT and LT, respectively, by identification of CD39 and CD73-activity and EPC-number and function, respectively.
Time Frame: may 08 to may 2010
Secondary Outcomes
No secondary outcomes reported